Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G2ZL
|
|||
| Former ID |
DIB004016
|
|||
| Drug Name |
Managlinat dialanetil
|
|||
| Synonyms |
CS-917; GP-3034; MB-05032; MB-06322; MB-06633; MB-6322; R-132917; Type 2 diabetes therapeutic, Gensia/Sankyo; Type 2 diabetes therapeutic, SICOR/Sankyo; Diabetes therapeutics, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, Gensia/Sankyo/Daiichi Sankyo; Purine nucleotide analogs, Metabasis/Sanyko/Daiichi Sankyo; Purine nucleotide analogs, SICOR/Sankyo/Daiichi Sankyo
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Company |
Metabasis Therapeutics Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H33N4O5PS
|
|||
| Canonical SMILES |
CCOC(=O)C(C)NP(C1=CC=C(O1)C2=C(SC(=N2)N)CC(C)C)NC(C)C(=O)OCC
|
|||
| InChI |
1S/C21H33N4O5PS/c1-7-28-19(26)13(5)24-31(25-14(6)20(27)29-8-2)17-10-9-15(30-17)18-16(11-12(3)4)32-21(22)23-18/h9-10,12-14,24-25H,7-8,11H2,1-6H3,(H2,22,23)/t13-,14-/m0/s1
|
|||
| InChIKey |
JGCMEVUWRCNKKE-KBPBESRZSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fructose-1,6-bisphosphatase (FBP) | Target Info | Modulator | [2] |
| BioCyc | Gluconeogenesis | |||
| KEGG Pathway | Glycolysis / Gluconeogenesis | |||
| Pentose phosphate pathway | ||||
| Fructose and mannose metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| AMPK signaling pathway | ||||
| Insulin signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Pathwhiz Pathway | Fructose and Mannose Degradation | |||
| Pentose Phosphate Pathway | ||||
| Gluconeogenesis | ||||
| Reactome | Gluconeogenesis | |||
| WikiPathways | Glycolysis and Gluconeogenesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00290940) Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917. U.S. National Institutes of Health. | |||
| REF 2 | MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.